Covid-19 vaccine-maker BioNTech to acquire former rival CureVac - Commersant

Retrieved on: 2025-06-18 05:40:52

Tags for this article:

Click the tags to see associated articles and topics

Covid-19 vaccine-maker BioNTech to acquire former rival CureVac - Commersant. View article details on hiswai:

Excerpt

Germany's BioNTech has signed a deal to acquire its former Covid-19 vaccine competitor CureVac for around $1.25 billion (€1.08 billion), ...

Article found on: commersant.ge